Quarterly ResultMay 12, 2026, 06:32 AM
ProMIS Neurosciences Secures $175M Financing; Phase 1b Trial on Track
AI Summary
ProMIS Neurosciences announced its Q1 2026 financial results and provided a corporate update, highlighting the successful closure of a PIPE financing that secured up to $175 million, including potential warrant exercises. This financing is expected to fund the company through 2027, covering the completion of its ongoing PRECISE-AD Phase 1b clinical trial for Alzheimer's disease. The trial is fully enrolled, with a blinded 6-month interim analysis expected in early Q3 2026 and 12-month top-line data in early 2027. The company reported a net loss of $8.2 million for the quarter, an increase from $7.3 million in the prior year, but ended with $63.8 million in cash and cash equivalents.
Key Highlights
- ProMIS Neurosciences closed PIPE financing for up to $175 million, including warrants.
- Secured $75.5 million in gross upfront proceeds from the private placement in February 2026.
- Cash and cash equivalents were $63.8 million as of March 31, 2026, up from $6.1 million on Dec 31, 2025.
- Cash runway is expected to fund operations through 2027, including PRECISE-AD trial completion.
- PRECISE-AD Phase 1b clinical trial is fully enrolled and progressing on schedule.
- Blinded 6-month interim analysis for PRECISE-AD is anticipated in early Q3 2026.
- 12-month top-line data for PRECISE-AD is anticipated in early 2027.
- Net loss for Q1 2026 was $8.2 million, compared to $7.3 million for Q1 2025.